PACB · Insider Trading
Pacific Biosciences of California, Inc.
Every open-market purchase and sale reported by PACB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-08 | James R Gibson II | See Remarks | MIXED | −161,815 | −$1.47M |
| 2026-08-18 | Mark Van Oene | See Remarks | Sell | −26,911 | −$30.41K |
| 2026-08-11 | Mark Van Oene | See Remarks | A | +489,130 | — |
| 2026-06-04 | Marshall Mohr | Director | A | +223,492 deriv. | — |
| 2026-06-04 | John F Milligan | Director | A | +223,492 deriv. | — |
| 2026-06-04 | Christopher M Smith | Director | A | +223,492 deriv. | — |
| 2026-06-04 | Kathy Ordonez | Director | A | +223,492 deriv. | — |
| 2026-06-04 | Christopher Gibson | Director | A | +74,497 deriv. | — |
| 2026-06-04 | Randall S Livingston | Director | A | +223,492 deriv. | — |
| 2026-06-04 | William W. Ericson | Director | A | +223,492 deriv. | — |
| 2026-06-04 | Hannah Valantine | Director | A | +223,492 deriv. | — |
| 2026-04-10 | Christopher Gibson | Director | A | +57,473 | — |
| 2026-04-03 | James R Gibson II | See Remarks | Sell | −88,185 | −$120.81K |
| 2026-03-05 | Christopher Gibson | Director | A | +53,913 | — |
| 2026-03-04 | Mark Van Oene | See Remarks | Sell | −6,504 | −$9.85K |
| 2026-03-04 | Christian O Henry | See Remarks | Sell | −12,497 | −$18.92K |
| 2026-03-04 | Michele Farmer | See Remarks | Sell | −2,979 | −$4.51K |
| 2026-03-03 | Michele Farmer | See Remarks | A | +89,835 | — |
| 2026-03-03 | Christian O Henry | See Remarks | A | +920,810 | — |
| 2026-03-03 | James R Gibson II | See Remarks | A | +333,848 | — |
| 2026-03-03 | Mark Van Oene | See Remarks | A | +500,000 | — |
| 2026-02-19 | Michele Farmer | See Remarks | Sell | −50,167 | −$79.86K |
| 2026-02-19 | Christian O Henry | See Remarks | Sell | −472,667 | −$752.39K |
| 2026-02-19 | Mark Van Oene | See Remarks | Sell | −184,897 | −$294.32K |
| 2025-08-20 | Mark Van Oene | See Remarks | Sell | −26,836 | −$35.18K |
| 2025-06-06 | Hannah Valantine | Director | A | +65,000 deriv. | — |
| 2025-06-06 | John F Milligan | Director | A | +65,000 deriv. | — |
| 2025-06-06 | Marshall Mohr | Director | A | +65,000 deriv. | — |
| 2025-06-06 | William W. Ericson | Director | A | +65,000 deriv. | — |
| 2025-06-06 | Kathy Ordonez | Director | A | +65,000 deriv. | — |
| 2025-06-06 | Christopher M Smith | Director | A | +32,500 deriv. | — |
| 2025-06-06 | Randall S Livingston | Director | A | +65,000 deriv. | — |
| 2025-06-06 | Lucy Shapiro | Director | A | +65,000 deriv. | — |
| 2025-05-21 | Michele Farmer | See Remarks | Sell | −5,195 | −$5.20K |
| 2025-04-02 | James R Gibson II | See Remarks | A | +1,000,000 | — |
| 2025-03-21 | Michele Farmer | See Remarks | A | +89,835 | — |
| 2025-03-21 | Mark Van Oene | See Remarks | A | +449,176 | — |
| 2025-03-21 | Christian O Henry | See Remarks | A | +920,810 | — |
| 2025-03-05 | Michele Farmer | See Remarks | Sell | −2,973 | −$4.18K |
| 2025-03-05 | Mark Van Oene | See Remarks | Sell | −6,486 | −$9.13K |
| 2025-03-05 | Christian O Henry | See Remarks | Sell | −12,497 | −$17.58K |
| 2025-02-19 | Christian O Henry | See Remarks | Sell | −259,909 | −$488.11K |
| 2025-02-19 | Michele Farmer | See Remarks | Sell | −24,349 | −$45.73K |
| 2025-02-19 | Mark Van Oene | See Remarks | Sell | −100,773 | −$189.25K |
| 2025-02-03 | Christopher M Smith | Director | A | +54,099 | — |
| 2025-01-10 | Mark Van Oene | See Remarks | Sell | −34,405 | −$69.98K |
| 2024-10-02 | Susan G. Kim | See Remarks | Sell | −19,782 | −$34.06K |
| 2024-09-17 | Christian O Henry | See Remarks | Sell | −98,907 | −$172.69K |
| 2024-08-20 | Mark Van Oene | See Remarks | Sell | −38,011 | −$63.17K |
| 2024-08-20 | Jeff Eidel | See Remarks | Sell | −26,760 | −$42.60K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| William W. Ericson | Director | 4,890,013 | $10.34M |
| Christian O Henry | See Remarks | 3,581,813 | $7.58M |
| Mark Van Oene | See Remarks | 2,705,853 | $5.72M |
| James R Gibson II | See Remarks | 1,083,848 | $2.29M |
| Kathy Ordonez | Director | 403,037 | $852.42K |
| Michele Farmer | See Remarks | 305,948 | $647.08K |
| John F Milligan | Director | 132,821 | $280.92K |
| Marshall Mohr | Director | 132,821 | $280.92K |
| Christopher Gibson | Director | 111,386 | $235.58K |
| Christopher M Smith | Director | 54,099 | $114.42K |
| Randall S Livingston | Director | 22,821 | $48.27K |
| Lucy Shapiro | Director | 22,821 | $48.27K |
| Hannah Valantine | Director | 22,821 | $48.27K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PACB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.